Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Decreased by WD Rutherford LLC

WD Rutherford LLC trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,719 shares of the medical research company’s stock after selling 680 shares during the quarter. Charles River Laboratories International makes up approximately 1.9% of WD Rutherford LLC’s holdings, making the stock its 24th largest position. WD Rutherford LLC’s holdings in Charles River Laboratories International were worth $3,177,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC boosted its position in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares during the period. Headlands Technologies LLC acquired a new position in Charles River Laboratories International during the 3rd quarter worth $37,000. Operose Advisors LLC acquired a new position in Charles River Laboratories International during the 3rd quarter worth $42,000. Venturi Wealth Management LLC boosted its position in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after acquiring an additional 112 shares during the period. Finally, Provence Wealth Management Group acquired a new position in Charles River Laboratories International during the 3rd quarter worth $57,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Up 0.5 %

Shares of NYSE CRL opened at $229.03 on Friday. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The firm has a market capitalization of $11.80 billion, a PE ratio of 24.87, a PEG ratio of 1.78 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The business has a 50-day moving average price of $253.48 and a two-hundred day moving average price of $222.64.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period last year, the company posted $2.98 EPS. The business’s quarterly revenue was down 7.9% compared to the same quarter last year. As a group, analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Guggenheim lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Citigroup upped their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. UBS Group upped their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. upped their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, Argus upped their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).